Neochem Bio FY26 PAT rises 62% to ₹1,203 lakh
Neochem Bio Solutions Limited reported a 62% increase in PAT to ₹1,203 lakh for FY26, with revenue growing 32% to ₹11,069 lakh. EBITDA increased 48% to ₹2,193 lakh, supported by a 52.7% capacity utilization. The Board approved the audited results on May 18, 2026, and an earnings call is scheduled for May 22, 2026.
*this image is generated using AI for illustrative purposes only.
Neochem Bio Solutions Limited has announced its audited financial results for the financial year ended March 31, 2026. The company reported a significant improvement in profitability, with Profit After Tax (PAT) rising by 62% to ₹1,203 lakh compared to the previous year. Revenue from operations increased by 32% to ₹11,069 lakh, driven by strong operational performance. Following the announcement, the company has scheduled an earnings conference call to discuss these results.
Financial Performance
The company's earnings before interest, taxes, depreciation, and amortization (EBITDA) grew by 48% to ₹2,193 lakh for FY26. The basic Earnings Per Share (EPS) stood at ₹8.71 for the year, calculated on the weighted average of outstanding shares following the company's Initial Public Offering (IPO) in December 2025.
| Metric | FY 2025-26 (₹ Lakhs) | FY 2024-25 (₹ Lakhs) | YoY Change |
|---|---|---|---|
| Revenue from Operations | 11,069 | 8,417 | +32% |
| EBITDA | 2,193 | 1,478 | +48% |
| PAT | 1,203 | 744 | +62% |
| EPS (Rs. Per Share) | 8.71* | 11.15 | - |
*The company completed its IPO in December 2025. The EPS reported is calculated on the weighted average of outstanding shares for the relevant period.
Board Approval and Audit
The Board of Directors approved the audited standalone financial results at its meeting held on May 18, 2026. M/s. Patel Mehta & Associates, Chartered Accountants, issued an audit report with an unmodified opinion on the financial statements. The auditors noted an emphasis of matter regarding a subsidy receivable of ₹485.40 lakhs, which remains unrealized and is dependent upon government approval.
Balance Sheet Highlights
The company's total equity and liabilities stood at ₹11,711.52 lakh as of March 31, 2026, up from ₹7,889.13 lakh in the previous year. Shareholders' funds increased significantly to ₹7,884.47 lakh, primarily due to the IPO proceeds. Total assets also rose to ₹11,711.52 lakh, with non-current assets at ₹3,119.72 lakh and current assets at ₹8,591.80 lakh.
Earnings Conference Call
Neochem Bio Solutions Limited has scheduled a conference call for analysts and investors on Friday, May 22, 2026, at 2:00 PM IST. The call will discuss the audited financial results for the half year and year ended March 31, 2026. Management participants include Mr. Swapnil Makati, Managing Director; Mr. Pradip Solanki, Chief Financial Officer; and Mr. Shamik Nagar, Associate Director, Business Operations. The presentation and audio recording will be available on the company's website.
Historical Stock Returns for Neochem Bio Solutions
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.59% | +4.47% | +36.60% | -7.02% | -7.02% | -7.02% |
How does Neochem Bio Solutions plan to deploy the IPO proceeds to sustain its current growth trajectory beyond FY26?
What is the timeline and likelihood of receiving government approval for the ₹485.40 lakh subsidy receivable, and how might its realization impact future cash flows?
Given the 32% revenue growth in FY26, what new markets, product segments, or capacity expansions is management targeting to maintain double-digit growth in FY27?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
